Copenhagen's Biograil raises €20M for oral drug delivery device
Copenhagen’s Biograil raises €20 million for oral drug delivery device designed as an alternative to injections
AI Overview
Copenhagen-based Biograil has closed a €20 million round backed by Verve Ventures and Megatrend Invest.
Why it matters
Biograil's BIONDD capsule aims to turn injectable biologics into swallowable oral doses, and the new capital funds the GLP and GMP work needed before Phase 1.